STOCK TITAN

Bristol-Myers Squibb Co. (BMY) Debt by Year

BMY NYSE

Bristol-Myers Squibb Co. carried $42.9B in long-term debt against $10.2B in cash and equivalents at the end of fiscal year 2025. Long-term debt fell 10.0% from the prior fiscal year. The table below carries 15 fiscal years, from 2011 to 2025, and the quarters Bristol-Myers Squibb Co. has filed alongside them.

FY2025 annual
Long-Term Debt $42.9B
Cash & Equivalents $10.2B
YoY -10.0%
5Y CAGR -2.4%
10Y CAGR +20.7%
Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

BMY Debt & Cash by Fiscal Year

Figures are in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricFY2510-KFY2410-KFY2310-KFY2210-KFY2110-KFY2010-KFY1910-KFY1810-KFY1710-KFY1610-KFY1510-KFY1410-KFY1310-KFY1210-KFY1110-K
Long-Term Debt$42.9B-10.0%$47.6B+29.9%$36.7B+4.6%$35.1B-11.5%$39.6B-18.1%$48.3B+11.4%$43.4B+668.5%$5.6B-19.1%$7.0B+22.0%$5.7B-12.7%$6.5B-9.6%$7.2B-9.3%$8.0B+21.5%$6.6B+22.2%$5.4B
Cash & Equivalents$10.2B-1.3%$10.3B-9.8%$11.5B+25.7%$9.1B-34.7%$14.0B-3.9%$14.5B+17.8%$12.3B+78.6%$6.9B+27.5%$5.4B+27.9%$4.2B+77.7%$2.4B-57.2%$5.6B+55.4%$3.6B+116.5%$1.7B-71.3%$5.8B

BMY Debt & Cash by Quarter

Figures are in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-QQ1'2410-QQ4'2310-K
Long-Term Debt$41.8B-5.9%$42.1B-5.3%$42.2B-8.7%$42.9B-10.0%$44.5B-8.6%$44.5B-9.0%$46.2B-6.7%$47.6B+29.9%$48.7B+51.5%$48.9B+41.0%$49.5B+41.1%$36.7B+4.6%
Cash & Equivalents$9.6B-39.1%$8.7B-30.8%$9.6B-12.0%$10.2B-1.3%$15.7B+99.3%$12.6B+100.2%$10.9B+16.6%$10.3B-9.8%$7.9B+5.0%$6.3B-24.8%$9.3B+3.7%$11.5B+25.7%

What long-term debt means

Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date.

More Bristol-Myers Squibb Co. financials

Frequently Asked Questions

Bristol-Myers Squibb Co. carried $42.9B in long-term debt against $10.2B in cash and equivalents at the end of fiscal year 2025.

Bristol-Myers Squibb Co. (BMY) long-term debt fell by 10.0% year over year, from $47.6B to $42.9B in fiscal year 2025.

Across the 15 fiscal years this page covers, Bristol-Myers Squibb Co. (BMY) long-term debt went from $5.4B in fiscal year 2011 to $42.9B in fiscal year 2025.

Bristol-Myers Squibb Co. (BMY) reported $41.8B in long-term debt in Q3 2026. This represents a decrease of 5.9% from the same quarter a year earlier.

Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date. This page lists what Bristol-Myers Squibb Co. (BMY) reported on that line in every period on record.